Rituximab in the Treatment of Primary Cutaneous B-Cell Lymphoma: A Review

被引：11
|
作者：
Fernandez-Guarino, M. [1 ]
Ortiz-Romero, P. L. [2 ]
Fernandez-Misac, R. [3 ]
Montalban, C. [4 ]
机构：
[1] Univ Alfonso X El Sabio, Hosp Cent Cruz Roja, Serv Dermatol, Madrid, Spain
[2] Univ Complutense, Hosp Univ 12 Octubre, Inst i 12, Fac Med, Madrid, Spain
[3] Hosp Univ Nuestra Senora Candelaria, Serv Dermatol, Santa Cruz de Tenerife, Spain
[4] Hosp Univ Ramon & Cajal, Serv Med Interna, Madrid, Spain
来源：
ACTAS DERMO-SIFILIOGRAFICAS | 2014年 / 105卷 / 05期
关键词：
Rituximab; Primary cutaneous B-cell lymphoma; Follicular lymphoma; Marginal zone lymphoma; Primary cutaneous diffuse large B-cell lymphoma leg type; Adverse effects;
D O I：
10.1016/j.ad.2012.10.021
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Rituximab is a chimeric mouse-human antibody that targets the CD20 antigen, which is found in both normal and neoplastic B cells. In recent years, it has been increasingly used to treat cutaneous B-cell lymphoma and is now considered an alternative to classic treatment (radiotherapy and surgery) of 2 types of indolent lymphoma, namely, primary cutaneous follicle center lymphoma and primary cutaneous marginal zone B-cell lymphoma. Rituximab is also administered as an alternative to polychemotherapy in the treatment of primary cutaneous large B-cell lymphoma, leg type. Its use as an alternative drug led to it being administered intralesionally, with beneficial effects. In the present article, we review the literature published on the use of rituximab to treat primary cutaneous B-cell lymphoma. (C) 2012 Elsevier Espana, S.L. and AEDV. All rights reserved.
引用
收藏
页码：438 / 445
页数：8
相关论文
共 50 条
  • [11] Cutaneous B-cell lymphoma treatment with rituximab: two cases.
    Viguier, M
    Bachelez, H
    Brice, P
    Rivet, J
    Dubertret, L
    [J]. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2002, 129 (10): : 1152 - 1155
  • [12] Treatment of Indolent Cutaneous B-Cell Lymphoma with Intralesional or Intravenous Rituximab
    Menzer, Christian
    Rendon, Adriana
    Hassel, Jessica C.
    [J]. CANCERS, 2022, 14 (19)
  • [13] Urticarial reaction localized to primary cutaneous B-cell lymphoma induced by rituximab
    Rimond, O.
    Morice, C.
    Moreau, A.
    Comoz, F.
    Verneuil, L.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 60 - 60
  • [14] Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab
    Morales, Anjali V.
    Advani, Ranjana
    Horwitz, Steven M.
    Riaz, Nadeem
    Reddy, Sunil
    Hoppe, Richard T.
    Kim, Youn H.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 59 (06) : 953 - 957
  • [15] Primary cutaneous B-cell lymphoma
    Bogle, MA
    Riddle, CC
    Triana, EM
    Jones, D
    Duvic, M
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 53 (03) : 479 - 484
  • [16] Primary cutaneous B-cell lymphoma
    Clayton, AS
    McCullough, M
    Barekman, CL
    [J]. CUTIS, 1998, 62 (02): : 69 - 72
  • [17] Primary cutaneous B-cell lymphoma: narrative review of the literature
    Grandi, Vieri
    Alberti Violetti, Silvia
    La Selva, Roberta
    Cicchelli, Stefano
    Delfino, Chiara
    Fava, Paolo
    Fierro, Maria T.
    Pileri, Alessandro
    Pimpinelli, Nicola
    Quaglino, Pietro
    Berti, Emilio
    [J]. GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2019, 154 (04): : 466 - 479
  • [18] Primary cutaneous B-cell lymphoma: Review and current concepts
    Pandolfino, TL
    Siegel, RS
    Kuzel, TM
    Rosen, ST
    Guitart, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (10) : 2152 - 2168
  • [19] Rituximab in heavily pretreated cutaneous B-cell lymphoma
    Zinzani, PL
    Stefoni, V
    Alinari, L
    Vianelli, N
    Baccarani, M
    [J]. LEUKEMIA & LYMPHOMA, 2003, 44 (09) : 1637 - 1638
  • [20] Primary cutaneous B-cell lymphoma mimicking pyoderma gangrenosum: first-line treatment with rituximab
    Lami, MC
    Vabres, P
    Dreyfus, B
    Germain, T
    Guillet, G
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 (01) : 250 - 252
12345